Your session is about to expire
← Back to Search
Chemotherapy + Bevacizumab + Tumor Treating Fields Therapy for Liver Cancer
Study Summary
This trial is testing a new combination of chemotherapy drugs with bevacizumab, and a new portable device that uses electrical fields to stop the growth of tumor cells, in people with cancer that has come back or does not respond to treatment and has spread to the liver.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I agree to use effective birth control during and for 30 days after the study.My kidney function is normal or only slightly reduced.I am still recovering from a major surgery or significant injury.I haven't had cancer treatment in the last 3 weeks, or within the specific times for certain drugs.My brain cancer symptoms are not controlled by medication and need high steroid doses.I do not have any severe illnesses that are not under control.My heart's electrical activity (QTc) is over 480 milliseconds or I have significant irregular heartbeats.My cancer does not respond to standard treatments or there are none available.My cancer has a specific genetic change related to the PI3K pathway.I may have radiation for symptom relief, not aimed at my main cancer spots.My liver cancer mainly spreads from another part and has a specific gene change.I have colorectal cancer that has mainly spread to my liver.Half of my cancer spread is in my liver.I have HIV, hepatitis B, or hepatitis C.You have had allergic reactions to the study drugs or any of their ingredients. You may also be sensitive to the hydrogels used on ECG stickers or TENS electrodes.My liver enzyme (ALT) levels are within the acceptable range.I am able to care for myself and up to being unable to work but can still move around.I haven't had a stroke, heart issues, serious stomach problems, or infections in my belly in the last 6 months.
- Group 1: Arm B(bevacizumab,liposomal doxorubicin, DAT, NovoTTF-100L[P])
- Group 2: Arm A (FOLFOX6, bevacizumab, NovoTTF-100L[P])
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Is there prior experience with Pegylated Liposomal Doxorubicin Hydrochloride research?
"At present, 1294 trials are being conducted on the efficacy of Pegylated Liposomal Doxorubicin Hydrochloride. Of those experiments, 373 have reached Phase 3 levels and 56730 sites across Guangzhou, Guangdong are running them."
Are there presently any opportunities to participate in this experiment?
"Based on the details available at clinicaltrials.gov, this research is still seeking participants. It was first advertised to potential enrollees in June 2020 and has been actively updated since then, with its most recent revision occurring on May 13th 2022."
Has the Food and Drug Administration granted authorization for Pegylated Liposomal Doxorubicin Hydrochloride?
"As this is a Phase 1 trial, with limited evidence of safety and efficacy, the risk associated with Pegylated Liposomal Doxorubicin Hydrochloride was estimated to be low at a score of 1."
What conditions commonly benefit from Pegylated Liposomal Doxorubicin Hydrochloride?
"Pegylated Liposomal Doxorubicin Hydrochloride is primarily employed to treat joints, but has also been found efficacious in treating typhus, HIV-associated Kaposi's sarcoma and Helicobacter pylori infections."
Has anything like this trial been conducted before?
"According to current information, there are 1294 ongoing studies for Pegylated Liposomal Doxorubicin Hydrochloride in 76 countries and 3205 cities. The first trial of this drug took place in 1997 and was sponsored by Alfacell. This Phase 3 clinical trial included 300 participants before its completion. Subsequently, 2922 additional trials have been conducted since then."
How many participants are being accepted for this experimental study?
"Affirmative. Clinicaltrials.gov has the most up-to-date information, which attests to this clinical trial's active recruitment drive that began on June 23rd 2020 and was last updated on May 13th 2022. 52 participants are needed from 1 medical centre for this endeavour."
Share this study with friends
Copy Link
Messenger